Congratulations to our CASS Foundation grant awardees

The grant awarded to Dr Garama will enable him to investigate mitochondrial protein import interactions. These interactions are critical for the metabolic changes that drive cancer formation and may provide new treatments and drug targets for some of the deadliest cancers.

Dr Wilson’s laboratory has previously demonstrated that a deadly population of ovarian cancer cells called ‘leader cells’ are responsible for invasion into healthy tissue. They are looking at targeting these cells as a novel therapy in a pre-clinical ovarian cancer model.

Primary aldosteronism is a condition due to excessive production of the hormone aldosterone by the adrenal gland, which causes high blood pressure and heart disease. An invasive procedure known as adrenal vein sampling (AVS) is usually performed to determine whether the overproduction of aldosterone is due to one adrenal gland (surgery will benefit) or both adrenal glands (medication is the treatment of choice). Dr Shen’s study will employ a non-invasive nuclear medicine 124I iodometomidate scan to determine if it is as good as the AVS for this purpose, with less waiting time and lower cost to the patient and health network.

Endometriosis is a chronic disorder that has a major impact on quality of life. There is no cure and current treatments are limited. We are investigating whether a new, naturally-produced cytokine can be used as a therapeutic for the disease. This project looks to characterise its activity on target cells in the endometrium and endometriotic lesions.

The project aims to identify novel drugs to slow the progression of Parkinson’s disease (PD) using preclinical human cellular models of PD.